Publ3 search

Z6_60GI02O0O8IDC0QEJUJ26TJDI4

> Publ3 search

Error:

Javascript is disabled in this browser. This page requires Javascript. Modify your browser's settings to allow Javascript to execute. See your browser's documentation for specific instructions.

Publikační činnost

Probíhá načítání, čekejte prosím...

Typ záznamu:	článek v odborném periodiku (J)
Domácí pracoviště:	Katedra interních oborů (11300)
Název:	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
Citace	Hájek, R., Mina, R., Petrucci, M., Spada, S., Patriarca, F., Cerrato, C., De Paoli, L., Pescosta, N., Ria, R., Malfitano, A., Musto, P., Baldini, L., Guglielmelli, T., Gamberi, B., Mannina, D., Benevolo, G., Zambello, R., Falcone, A., Palumbo, A. a Nagler, A. et al. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2018, 8(18), s. 533-540. ISSN 2152-2650.

Podnázev
Rok vydání:	2018
Obor:
Kód ISSN:	2152-2650
Oficiální název periodika:	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Stát vydavatele periodika:	Spojené státy americké
Svazek periodika:	8
Číslo periodika v rámci svazku:	18
Číslo článku:
Ročník:
Počet stran článku:	8
Strana od:	533
Strana do:	540
Kód UT WoS:	000439422100009
EID:	2-s2.0-85048391821
Poddruh recenzovaného článku:	Článek v impaktovaném časopise (Jimp)

Klíčová slova anglicky:	ASCT; CR; Lenalidomide; MM; Treatment intensification
Popis v původním jazyce:	In patients with a complete response (CR), high-dose therapy with autologous stem cell transplantation (HDT-ASCT) consolidation improved progression-free survival (PFS), second PFS (PFS2), and overall survival (OS) versus R-Alk (lenalidomide, alkylator) consolidation. Also, lenalidomide maintenance therapy enhanced PFS compared with no maintenance therapy. The survival advantage with HDT-ASCT compared with R-Alk in CR patients can be attributed to the greater minimal residual disease negativity rate induced by HDT-ASCT. Background: High-dose therapy with autologous stem cell transplantation (HDT-ASCT) and maintenance treatment with novel agents are the best options for patients with newly diagnosed multiple myeloma, increasing the rate of complete response (CR) and prolonging progression-free survival (PFS) and overall survival (OS). Indeed, the achievement of a CR is a predictor of long-term survival among transplant-eligible patients. However, it is unclear whether patients reaching a CR after induction treatment could receive less intense consolidation or avoid maintenance therapy. Patients and Methods: We analyzed CR patients treated in 2 phase III trials, GIMEMA-RV-MM-PI-209 and RV-MM-EMN-441, to compare HDT-ASCT with an R-Alk (lenalidomide, alkylator) regimen as consolidation, and lenalidomide (R) maintenance with no maintenance. The primary endpoints were PFS, second PFS (PFS2), and OS from consolidation and maintenance (_m). Results: Overall, the data from 166 patients in CR were analyzed, 95 in the HDT-ASCT group and 71 in the R-Alk group. The CR patients who received HDT-ASCT had a better PFS (hazard ratio [HR], 0.55; P = .01), PFS2 (HR, 0.46; P = .02), and OS (HR, 0.42; P = .03) compared with patients randomized to R-Alk. The survival benefit with HDT-ASCT was confirmed among all the subgroups, according to age, International Staging System (ISS stage, cytogenetic profile, and receipt of maintenance therapy. CR patients who received lenalidomide maint
Popis v anglickém jazyce:

Seznam ohlasů

Ohlas

R01:	RIV/61988987:17110/18:A1901YVL

Complementary Content

${loading}